Glyphic Biotechnologies Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Glyphic Biotechnologies is a biotechnology startup focused on proteomics, headquartered in Berkeley, California. The company aims to sequence proteins to reveal how biological systems function, offering a next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease. It has a small to mid-sized team and was founded in New York in 2021 by Daniel Estandian and Joshua Yang. Recent coverage in December 2024 notes the company is developing a protein sequencing platform capable of analyzing the sequence of each protein in a complex mixture. Its target customers are researchers in biology and disease-related proteomics, including academic and industrial researchers who study proteins and their roles. The company operates within the biotechnology research industry, seeking to position itself as a provider of advanced proteomics capabilities that extend beyond DNA-derived insights.